Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of docetaxel, cisplatin and capecitabine (TCX) in advanced gastric cancer
2007-000725-22Phase 2Active
- Sponsor
- ACROI
- Start
- May 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and capecitabine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by ACROI. Primary endpoint: Primary objective. Started May 2007; status: active.
02
Drugs
docetaxelcisplatincapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2007-000725-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000725-22.